Get Started
HBV Curricula
Step 1
These independent CME/CE activities are supported by educational grants from Bristol-Myers Squibb

Gilead Sciences, Inc.



The Advanced Certificate Program in Chronic Hepatitis B Management IV
Bridging Cultural Differences to Improve HBV Treatment
in Asian and Other Diverse Communities
  1. Curriculum VII
  2. Curriculum VI
  3. Curriculum V
  4. Curriculum IV
  5. Full Course List
CME/CE Information

Target Audience

This CME/CE activity is designed for gastroenterologists, hepatologists, infectious disease specialists, nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians, including primary care providers and oncologists, with a special interest in hepatitis B infection.

Activity Goal

The goal of this CME/CE activity is to increase clinicians’ awareness of HBV disease prevalence and diagnostic methodology within the high-risk HBV patient populations, provide current and emerging strategies for the selection of patients for treatment, educate on current treatment options, and expand on treatment management skills for HBV-infected patients.

Learning Objective (s)

  • Assess the importance of screening, diagnosis, and optimal treatment intervention of patients with or at risk of developing HBV through an understanding of the epidemiology, risk factors, and disease burden imposed by HBV, including cirrhosis, HCC, morbidity, and mortality.
  • Assess the impact of cultural differences on patient communication and management of HBV infection (comparing the Asian and Pacific Islander, Latino, African-American, and Caucasian communities) to bridge these differences and improve patient outcomes.
  • Assess the role of HBV DNA and other markers in determining when to treat and optimal treatment selection in HBV-infected patients with diverse ethnic backgrounds, and in evaluating on-treatment response to therapy to improve patient outcomes.
  • Evaluate the role of genotypes in determining prognosis and selection of treatment to provide HBV-infected patients with improved outcomes.
  • Integrate HBV vaccination intervention into prevention strategies to reduce the incidence and prevalence of HBV and improve patient outcomes.
  • Formulate anti-HBV treatment strategies, considering safety, efficacy, endpoints, and resistance patterns of currently available and emerging antiviral agents as well as cultural differences among patients, to improve response rates in patients with HBV infection.
  • Integrate prescribing and monitoring strategies to help prevent or reduce the emergence of resistance into individualized anti-HBV treatment plans for infected patients.


CME Information: Physicians


Statement of Accreditation

Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge® designates this educational activity for a maximum of 16.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Information: Nurses

Specific credit information can be found on each activity's web page.

CE Information: Pharmacists

Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

CME/CE Instructions


To obtain CME/CE credit:

  1. Read or listen to each activity carefully.
  2. Complete/submit each posttest and evaluation.
  3. Instantly access and print out your certificate.

There is no fee for this activity.

CONTRACT FOR MUTUAL RESPONSIBILITY IN CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here.
Disclosure Information

The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Bristol-Myers Squibb, Gilead Sciences, Inc, GlobeImmune, Inc, Hoffman-La Roche, Inc, Idenix Pharmaceuticals, Pharmasset Pharmaceuticals Inc, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, GlobeImmune, Inc, Hoffman-La Roche, Inc, Idenix Pharmaceuticals, Inc, Metabasis Therapeutics, Novartis Pharmaceuticals Corporation, and Vertex Pharmaceuticals Incorporated.

Robert G. Gish, MD has received grant/research support from Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, Idenix Pharmaceuticals Inc, InterMune Inc, Ortho Biotech Products, LP, Pfizer, Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, and Valeant Pharmaceuticals International; is a consultant for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Chiron Corporation, Corixa Corporation, Gilead Sciences, Inc, GlaxoSmithKline, HepaHope, Inc, Hoffmann-La Roche Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, InterMune Pharmaceuticals, Inc, Metabasis Therapeutics, Inc, Ortho Biotech Products, LP, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and ZymoGenetics, Inc; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche Inc, Schering-Plough Corporation, and Three Rivers Pharmaceuticals International.

Steven-Huy B. Han, MD, AGAF has received grant/research support from Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; is a consultant for and has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, Pharmasset Pharmaceuticals, Inc, and Novartis Pharmaceuticals Corporation; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation.

W. Ray Kim, MD has received grant/research support from Gilead Sciences, Inc; is a consultant for and is on the advisory boards of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffman-La Roche, Inc, and Schering-Plough Corporation.

Naoky C.S. Tsai, MD has received grant/research support from and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; and has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, and Novartis Pharmaceuticals Corporation.

John W. Ward, MD

Peer Reviewer has disclosed no significant relationships.

Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.

Projects In Knowledge's staff members have no significant relationships to disclose.

These activities may contain discussions of unlabeled/unapproved uses of drugs or devices. Specific product disclosure will be forthcoming in each activity.

The opinions expressed in these activities are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

These independent CME/CE activities are supported by educational grants from Bristol-Myers Squibb

Gilead Sciences, Inc.

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

1874






FIFA 14 Coins | WildStar Gold | WildStar Platinum | Fifa 14 Coins | Fifa Ultimate Team Coins | FIFA 14 Coins | Fut 14 Coins | Tattoo Supplies | Tattoo Kits | FIFA 14 Coins | Replica Handbags | Sexy Lingerie | FIFA 14 Coins | Wedding Dresses | Tattoo Supplies | Iphone 5s case | Wedding Dresses | Fashion Shoes | Wedding Dresses